Mary Bird Perkins Cancer Center - Baton Rouge — Baton Rouge, Louisiana

Mary Bird Perkins Cancer Center - Baton Rouge is a clinical research site located in Baton Rouge, Louisiana, United States 70809.

Crixeo Clinical Trials Trust Score: 27/100 (FAILING). This profile has not yet been claimed by the site owner.

Mary Bird Perkins Cancer Center - Baton Rouge has participated in 53 clinical trials with 3 currently active.

Therapeutic areas: Breast Cancer, Sarcoma, Pancreatic Cancer.

Sponsors: Alliance for Clinical Trials in Oncology, Eli Lilly and Company, SWOG Cancer Research Network.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Baton Rouge

Browse all research sites in Louisiana · View every site in Baton Rouge

Sponsor Feasibility Report

Trust Score: 27/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Mary Bird Perkins Cancer Center - Baton Rouge?

Mary Bird Perkins Cancer Center - Baton Rouge has a Crixeo Trust Score of 27/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Mary Bird Perkins Cancer Center - Baton Rouge conducted?

Mary Bird Perkins Cancer Center - Baton Rouge has 53 clinical trials on record, with 3 currently active. Their work covers Breast Cancer, Sarcoma, Pancreatic Cancer.

Is Mary Bird Perkins Cancer Center - Baton Rouge accredited by Crixeo Clinical Trials?

Mary Bird Perkins Cancer Center - Baton Rouge has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Mary Bird Perkins Cancer Center - Baton Rouge?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.